This Week's Biggest Medtech Deals Have One Thing in Common: De-Risked Regulatory Pathways

Five large financings and deals in a single week. When money moves that fast, what is it really paying for?

Our reading is that investors are paying for regulatory risk that has already been cleared. For earlier-stage companies, that makes the Clinical Evaluation Report (CER) and the wider compliance file part of what gets priced in a funding or M&A conversation. This is our interpretation: the reports do not state the investors' reasoning.

What happened in the week of 2 October 2026?

The Nelson Advisors roundup of 2 October 2026 logged these moves:

• AstraZeneca took a $2 billion equity stake in Summit Therapeutics.
• Sanofi committed $1 billion upfront to expand its alliance with Regeneron.
• Telix finalised terms on its transaction with ITM, valued at up to $2.35 billion.
• Sofinnova Partners closed an €82 million fund for up to eight early-stage medical device startups.
• AnaCardio raised $70.9 million to advance clinical development of heart failure treatments.

The three largest deals alone are worth up to about $5.35 billion. Most of them are pharma and radiopharmaceutical deals, so the lesson for devices is by analogy, not direct proof.

Is there a common thread?

Partly. The roundup describes the three biggest deals as deepening an existing commitment, expanding an existing alliance and consolidating production. None reads as a first bet on an unproven pathway.

Two items cut the other way. The Sofinnova fund targets early-stage device startups, and AnaCardio is still in clinical development. Early money still flows, but it arrives with expectations. One week of news is not a trend, and we cannot see any term sheets.

What do investors see in your regulatory file?

During due diligence (the buyer's or investor's detailed check), your regulatory documents show how much risk sits between today and revenue. Under the EU MDR (Regulation (EU) 2017/745), Article 61 requires a clinical evaluation that is kept up to date with post-market data throughout the device's life. A CER that is thin, stale or hard to trace is a visible gap.

Gaps found early can be fixed on your timeline. Gaps found during diligence tend to turn into delays or price discussions. We cover the buyer's side in our device handover checklist.

What should early-stage teams have in shape?

Before you open a data room, check that you can show:

1. Clear clinical claims. Each claim should link to evidence.
2. A documented literature search. Keep the protocol, the dates and the results.
3. A justified evidence strategy. If you rely on equivalence or existing data, explain why it is enough.
4. A PMCF plan that links to the CER. Post-market clinical follow-up (PMCF) shows how evidence will keep growing after launch.
5. A change log and update triggers. Reviewers should see what changed, when and why.
6. A pathway map. Device class, conformity route, notified body and expected timeline.

A living CER makes this far easier. We describe how to build one in our article on CER strategy and the MDR reform.

When should you start?

Before the round, and by months, not weeks. Picture a team that opens its data room and is asked for the CER. If the only version is a two-year-old draft, the conversation shifts from the device to the paperwork.

Key takeaways

• Five deals in one week suggest capital is concentrating where regulatory risk is lower, though the reports do not say this.
• Most of the deals are pharma, so apply the lesson to devices with care.
• Under MDR Article 61, the CER must be kept current, so staleness is a visible risk.
• Fix gaps before diligence starts, not after a term sheet arrives.
• A well-kept CER is a fundraising asset as well as a submission requirement.

FAQ

Does a strong CER raise a company's valuation?

We cannot promise that. What we can say is that it removes a risk reviewers would otherwise price in or use to slow the deal.

Do these pharma deals involve CERs?

No. A CER is a medical device document under the MDR. Medicines follow a different regulatory route.

How early should we start CER work?

As early as your device concept and claims are clear, and well before you plan to raise. Starting early also avoids a rushed rebuild.

Will the proposed MDR reform change this?

The Commission's proposal is not yet law, and it does not remove clinical evaluation. See our article on the reform for details.

Planning a raise or a sale? Contact the Qmedify Regulatory Team and we will review your CER and regulatory file before investors do.